Argenica Therapeutics Ltd (AU:AGN) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Argenica Therapeutics has enhanced its board with the addition of Dr. Mark Etherton and Mr. Rob Black, bringing in a wealth of expertise in neurology drug development and financial markets. The appointments are set to bolster Argenica’s transition into a pharmaceutical development company, focusing on novel therapeutics for brain injuries and neurodegenerative diseases. The company is actively pursuing clinical trials for its lead neuroprotective peptide candidate, ARG-007, aimed at improving outcomes for stroke and other brain injury patients.
For further insights into AU:AGN stock, check out TipRanks’ Stock Analysis page.